Clinical Trials Directory

Trials / Completed

CompletedNCT02165618

Rationalisation of Polypharmacy by the Geriatric Consultation Team

Rationalisation of Polypharmacy by the Geriatric Consultation Team Using the RASP List: a Pilot Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Academic / Other
Sex
All
Age
75 Years
Healthy volunteers
Accepted

Summary

Polypharmacy is a common problem in elderly, leading among others to increased adverse drug events. The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team using the RASP (Rationalisation of drugs on admission by an adjusted STOPP\*-list in older patients) list could reduce inappropriate prescribing for elderly admitted patients, admitted to non-geriatric departments. (\* = Screening Tool of Older Persons' potentially inappropriate Prescriptions)

Detailed description

Polypharmacy and (potentially) inappropriate prescribing is highly prevalent in the older population, associated with increase health care expenditures, morbidity and avoidable adverse events . The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team (GCT) using the RASP (Rationalisation of drugs on admission by an adjusted STOPP-list in older patients) list could reduce inappropriate prescribing for older admitted patients, admitted to non-geriatric departments. The GCT could offer the ideal format to deliver the intervention to a broad older hospitalised population.

Conditions

Interventions

TypeNameDescription
OTHERMedication review, based on but not limited to the RASP listSystematic approach: 1. Medication reconciliation 2. Applying the RASP list 3. Expert review (not based on the RASP list) 4. Multidisciplinary discussion

Timeline

Start date
2014-01-01
Primary completion
2014-02-01
Completion
2014-02-01
First posted
2014-06-17
Last updated
2014-06-17

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT02165618. Inclusion in this directory is not an endorsement.